Novo Nordisk - 42 Year Stock Price History | NVO
Historical daily share price chart and data for Novo Nordisk since 1982 adjusted for splits and dividends. The latest closing stock price for Novo Nordisk as of April 23, 2024 is 128.64.
- The all-time high Novo Nordisk stock closing price was 134.95 on March 07, 2024.
- The Novo Nordisk 52-week high stock price is 138.28, which is 7.5% above the current share price.
- The Novo Nordisk 52-week low stock price is 75.56, which is 41.3% below the current share price.
- The average Novo Nordisk stock price for the last 52 weeks is 99.74.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Novo Nordisk Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2024 |
119.7841 |
101.3779 |
134.9455 |
101.3779 |
128.6400 |
25.25% |
| 2023 |
84.0039 |
67.1462 |
104.6939 |
64.8812 |
102.7083 |
54.79% |
| 2022 |
53.4108 |
52.5461 |
66.3520 |
44.9677 |
66.3520 |
22.65% |
| 2021 |
42.6120 |
33.8575 |
56.5502 |
31.7861 |
54.0965 |
63.39% |
| 2020 |
30.4984 |
27.0728 |
34.9809 |
22.9442 |
33.1086 |
23.31% |
| 2019 |
23.6092 |
21.5184 |
27.0264 |
21.3206 |
26.8502 |
26.73% |
| 2018 |
21.9775 |
24.2642 |
26.0473 |
19.1039 |
21.1873 |
-11.88% |
| 2017 |
19.0119 |
15.6104 |
24.0715 |
14.3327 |
24.0447 |
54.29% |
| 2016 |
20.8802 |
24.2359 |
24.7515 |
13.7199 |
15.5843 |
-36.56% |
| 2015 |
22.6286 |
17.7037 |
25.4752 |
17.4579 |
24.5658 |
39.32% |
| 2014 |
18.4223 |
15.0164 |
20.4286 |
15.0164 |
17.6329 |
16.69% |
| 2013 |
13.9144 |
13.3036 |
15.5829 |
12.3126 |
15.1105 |
15.44% |
| 2012 |
11.7689 |
9.2177 |
13.6429 |
9.0995 |
13.0895 |
44.10% |
| 2011 |
9.0860 |
8.6356 |
10.3581 |
7.4539 |
9.0838 |
3.90% |
| 2010 |
6.6634 |
5.0080 |
8.7428 |
4.9096 |
8.7428 |
79.47% |
| 2009 |
4.2780 |
3.9415 |
5.2895 |
3.2021 |
4.8714 |
27.03% |
| 2008 |
4.4808 |
4.7004 |
5.4496 |
3.2849 |
3.8348 |
-19.75% |
| 2007 |
3.9099 |
3.0305 |
5.0135 |
2.9866 |
4.7785 |
57.36% |
| 2006 |
2.4346 |
2.0329 |
3.0628 |
1.9611 |
3.0367 |
51.05% |
| 2005 |
1.8956 |
1.8656 |
2.1390 |
1.7325 |
2.0104 |
5.26% |
| 2004 |
1.7284 |
1.4286 |
1.9364 |
1.3576 |
1.9100 |
34.61% |
| 2003 |
1.2049 |
1.0027 |
1.4189 |
0.8646 |
1.4189 |
43.96% |
| 2002 |
1.0789 |
1.3546 |
1.3847 |
0.7609 |
0.9856 |
-27.24% |
| 2001 |
1.3592 |
1.1922 |
1.5616 |
1.1721 |
1.3546 |
14.19% |
| 2000 |
1.1511 |
0.8955 |
1.5094 |
0.8248 |
1.1863 |
37.85% |
| 1999 |
0.7714 |
0.9228 |
0.9228 |
0.6380 |
0.8606 |
-2.00% |
| 1998 |
0.9250 |
0.9373 |
1.1176 |
0.7148 |
0.8782 |
-7.45% |
| 1997 |
0.7051 |
0.5892 |
0.9505 |
0.5761 |
0.9489 |
55.02% |
| 1996 |
0.4838 |
0.4558 |
0.6202 |
0.4150 |
0.6121 |
37.24% |
| 1995 |
0.3612 |
0.3021 |
0.4460 |
0.2924 |
0.4460 |
45.32% |
| 1994 |
0.3221 |
0.3183 |
0.3554 |
0.2843 |
0.3069 |
-3.58% |
| 1993 |
0.2865 |
0.2820 |
0.3183 |
0.2508 |
0.3183 |
12.24% |
| 1992 |
0.2812 |
0.2881 |
0.3075 |
0.2539 |
0.2836 |
-0.18% |
| 1991 |
0.2225 |
0.1960 |
0.2936 |
0.1795 |
0.2841 |
44.65% |
| 1990 |
0.1620 |
0.1548 |
0.2020 |
0.1389 |
0.1964 |
25.90% |
| 1989 |
0.1370 |
0.1193 |
0.1618 |
0.1193 |
0.1560 |
30.76% |
| 1988 |
0.0997 |
0.0699 |
0.1285 |
0.0699 |
0.1193 |
84.67% |
| 1987 |
0.1011 |
0.0991 |
0.1252 |
0.0608 |
0.0646 |
-34.28% |
| 1986 |
0.0920 |
0.0859 |
0.1029 |
0.0788 |
0.0983 |
12.99% |
| 1985 |
0.0833 |
0.0703 |
0.1029 |
0.0685 |
0.0870 |
23.76% |
| 1984 |
0.1238 |
0.1677 |
0.1810 |
0.0637 |
0.0703 |
-57.60% |
| 1983 |
0.1733 |
0.1255 |
0.2154 |
0.1255 |
0.1658 |
27.64% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$562.108B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
